Cahaba Wealth Management Inc. Raises Position in Johnson & Johnson $JNJ

Key Points

• Cahaba Wealth Management Inc. increased its holdings in Johnson & Johnson by 28.2% during the 2nd quarter, owning 6,931 shares valued at approximately $1.06 million.
• Executive Vice President Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock for over $10 million, representing a 24.08% decrease in her holdings.
• Analysts have shown optimism with a consensus rating of "Moderate Buy" and an average target price of $181.40 for Johnson & Johnson stock, reflecting confidence in its future performance.

Cahaba Wealth Management Inc. boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 28.2% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,931 shares of the company's stock after buying an additional 1,523 shares during the period. Cahaba Wealth Management Inc.'s holdings in Johnson & Johnson were worth $1,059,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Highline Wealth Partners LLC increased its stake in shares of Johnson & Johnson by 51.8% in the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. purchased a new stake in shares of Johnson & Johnson during the first quarter worth about $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson during the first quarter worth about $52,000. 69.55% of the stock is owned by institutional investors.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of research firms recently commented on JNJ. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Bank of America increased their price target on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Barclays raised their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, The Goldman Sachs Group boosted their target price on Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a research note on Friday, September 19th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $181.40.

Johnson & Johnson Stock Up 1.1%

Shares of NYSE:JNJ opened at $179.69 on Friday. The firm's 50-day simple moving average is $174.41 and its 200-day simple moving average is $162.06. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a market cap of $432.75 billion, a price-to-earnings ratio of 19.22, a PEG ratio of 2.29 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the firm posted $2.82 EPS. The firm's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.